IL10 and type 1 diabetes mellitus: As was the case for the TR1 cells arising in response to T1D and EAE-specific pMHC class II-NPs 1, mAb-based in vivo blockade of IL-10 and TGFβ in pMHC-NP-treated NOD.c3c4 mice showed that the therapeutic effects of PDC-E2166–181/IAg7-NPs required these two TR1 cell-derived cytokines (Fig. 4a–c).